Federated Hermes’s Fulcrum Therapeutics FULC Stock Holding History

Federated Hermes’s Portfolio FULC Stock Details FULC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$2.52K	Hold	328	–	–	﹤0.01%	1954
2025 Q4	$3.71K	Hold	328	–	–	﹤0.01%	1919
2025 Q3	$3.02K	Buy	+328	New	+$2.37K	﹤0.01%	1994
2024 Q4	–	Sell	-25,401	Closed	-$90.7K	–	2118
2024 Q3	$90.7K	Buy	+25,401	New	+$188K	﹤0.01%	1578
2023 Q2	–	Sell	-1,385	Closed	-$3.95K	–	2150
2023 Q1	$3.95K	Buy	+1,385	New	+$12.4K	﹤0.01%	1954
2021 Q4	–	Sell	-71	Closed	-$2K	–	2237
2021 Q3	$2K	Sell	71 -587	-89%	-$11.1K	﹤0.01%	2094
2021 Q2	$7K	Buy	+658	New	+$6.65K	﹤0.01%	2008

Other funds holding FULC

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

FTM

First Turn Management Del Mar, California $895M AUM 261.28% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return

Federated Hermes's FULC Position: Q1 2026 in Review

Federated Hermes held its Fulcrum Therapeutics (FULC) position steady in Q1 2026 at 328 shares worth $2.52K. The position accounts for ﹤0.01% of the portfolio, ranked #1954.

Federated Hermes first reported a position in FULC in Q2 2021 and has held it in 7 quarters since. The position peaked at $90.7K in Q3 2024. 169 funds tracked by Wall St. Rank hold FULC as of Q1 2026.

Federated Hermes held 328 shares of Fulcrum Therapeutics worth $2.52K as of Q1 2026.
Federated Hermes left its Fulcrum Therapeutics share count unchanged in Q1 2026.
Fulcrum Therapeutics made up ﹤0.01% of Federated Hermes's portfolio in Q1 2026, its #1954 holding.
Federated Hermes first reported a position in Fulcrum Therapeutics in Q2 2021 and has held it in 7 quarters since.
Federated Hermes's Fulcrum Therapeutics position peaked at $90.7K in Q3 2024.
169 funds tracked by Wall St. Rank held Fulcrum Therapeutics as of Q1 2026.

Based on Federated Hermes's 13F filing for Q1 2026, filed 11 May 2026.